These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 38522059)
1. Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis. Erdinest N; Noyman DBE; London N; Lavy I; Levinger N; Landau D; Solomon A; Morad Y; Naroo SA Int Ophthalmol; 2024 Mar; 44(1):157. PubMed ID: 38522059 [TBL] [Abstract][Full Text] [Related]
2. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889 [TBL] [Abstract][Full Text] [Related]
3. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Vichyanond P; Kosrirukvongs P Curr Allergy Asthma Rep; 2013 Jun; 13(3):308-14. PubMed ID: 23625179 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus. Malhotra C; Singh H; Jain AK; Gupta A; Ram J Ocul Immunol Inflamm; 2022 Jul; 30(5):1083-1091. PubMed ID: 33764241 [TBL] [Abstract][Full Text] [Related]
10. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. Liendo VL; Vola ME; Barreiro TP; Wakamatsu TH; Gomes JÁP; Santos MSD Arq Bras Oftalmol; 2017; 80(4):211-214. PubMed ID: 28954018 [TBL] [Abstract][Full Text] [Related]
11. Immunopathological Features of Severe Chronic Atopic Keratoconjunctivitis and Effects of Topical Cyclosporine Treatment. Utine CA; Stern M; Akpek EK Ocul Immunol Inflamm; 2019; 27(7):1184-1193. PubMed ID: 30189151 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis. Wan Q; Tang J; Han Y; Wang D; Ye H Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239 [TBL] [Abstract][Full Text] [Related]
13. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study. Leonardi A; Doan S; Amrane M; Ismail D; Montero J; Németh J; Aragona P; Bremond-Gignac D; Ophthalmology; 2019 May; 126(5):671-681. PubMed ID: 30593775 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Keklikci U; Soker SI; Sakalar YB; Unlu K; Ozekinci S; Tunik S Jpn J Ophthalmol; 2008; 52(5):357-362. PubMed ID: 18991035 [TBL] [Abstract][Full Text] [Related]
15. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Vichyanond P; Pacharn P; Pleyer U; Leonardi A Pediatr Allergy Immunol; 2014 Jun; 25(4):314-22. PubMed ID: 24438133 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Pucci N; Caputo R; Mori F; De Libero C; Di Grande L; Massai C; Bernardini R; Novembre E Int J Immunopathol Pharmacol; 2010; 23(3):865-71. PubMed ID: 20943058 [TBL] [Abstract][Full Text] [Related]
17. Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial. Keklikci U; Dursun B; Cingu AK Adv Clin Exp Med; 2014; 23(3):455-61. PubMed ID: 24979519 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Yazu H; Shimizu E; Aketa N; Dogru M; Okada N; Fukagawa K; Fujishima H Ann Allergy Asthma Immunol; 2019 Apr; 122(4):387-392.e1. PubMed ID: 30639466 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of medical treatments for vernal keratoconjunctivitis: A systematic review and meta-analysis. Roumeau I; Coutu A; Navel V; Pereira B; Baker JS; Chiambaretta F; Bremond-Gignac D; Dutheil F J Allergy Clin Immunol; 2021 Sep; 148(3):822-834. PubMed ID: 33819510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]